AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Privia Health 2025 Q2 Earnings Misses Targets as Net Income Slips 33.3%
Generated by AI AgentAinvest Earnings Report Digest
Friday, Aug 8, 2025 2:41 am ET1min read
Aime SummaryPrivia Health (PRVA) reported its fiscal 2025 Q2 earnings on August 7, 2025. The company raised full-year guidance for several metrics but missed earnings expectations, with a sharp decline in EPS and net income.
The results show a mixed performance as the company continues to expand its footprint and refine its business model.
Revenue
Privia Health’s total revenue surged 23.4% year-over-quarter to $521.15 million, driven by strong growth in its fee-for-service (FFS) and capitated revenue streams. FFS-patient care revenue reached $331.46 million, while capitated revenue hit $75.51 million. Shared savings and care management fees also posted gains, contributing $60.02 million and $16.92 million, respectively. Administrative services and other revenue accounted for the remaining portions of the total.
Earnings/Net Income
Despite robust revenue growth, Privia Health’s earnings underperformed. Earnings per share (EPS) declined 33.3% year-over-quarter to $0.02, and net income fell to $3.29 million, a 29.2% drop from $4.64 million in the prior year.
Price Action
Following the earnings release, Privia Health’s stock experienced a downturn, with a 2.45% decline during the latest trading day and a 9.34% drop month-to-date.
Post-Earnings Price Action Review
A backtest of a strategy that buys shares after a revenue increase and holds for 30 days yielded poor results over the past three years, with a return of -32.69%. This significantly underperformed the benchmark return of 51.69%. The strategy recorded a CAGR of -12.53% and a maximum drawdown of 0.00%, highlighting the inherent risks and volatility associated with this approach.
CEO Commentary
CEO Parth Mehrotra emphasized Privia Health’s strong performance, citing 13.8% year-over-year implemented provider growth and 15.2% value-based lives attribution growth. He noted the company’s differentiated model—combining medical groups, risk-bearing, and a tech platform—as a driver of consistent financial performance. Mehrotra expressed confidence in the business model and optimism about growth from new provider signings and operational execution.
Guidance
Privia Health raised its full-year 2025 guidance for Practice Collections, GAAP Revenue, Platform Contribution, and Adjusted EBITDA to above the high end of initial ranges. The company expects over 80% of full-year adjusted EBITDA to convert to free cash flow and anticipates ending 2025 with more than $450 million in cash, assuming no further capital deployment.
Additional News
Recent developments include the company’s $95 million acquisition of an IMS transaction in Arizona, signaling a strategic move to expand its market presence. also announced plans to host a conference call on August 7, 2025, to discuss its financial results and future outlook. No major executive changes or dividend announcements were reported within the specified timeframe.
The results show a mixed performance as the company continues to expand its footprint and refine its business model.
Revenue
Privia Health’s total revenue surged 23.4% year-over-quarter to $521.15 million, driven by strong growth in its fee-for-service (FFS) and capitated revenue streams. FFS-patient care revenue reached $331.46 million, while capitated revenue hit $75.51 million. Shared savings and care management fees also posted gains, contributing $60.02 million and $16.92 million, respectively. Administrative services and other revenue accounted for the remaining portions of the total.
Earnings/Net Income
Despite robust revenue growth, Privia Health’s earnings underperformed. Earnings per share (EPS) declined 33.3% year-over-quarter to $0.02, and net income fell to $3.29 million, a 29.2% drop from $4.64 million in the prior year.
Price Action
Following the earnings release, Privia Health’s stock experienced a downturn, with a 2.45% decline during the latest trading day and a 9.34% drop month-to-date.
Post-Earnings Price Action Review
A backtest of a strategy that buys shares after a revenue increase and holds for 30 days yielded poor results over the past three years, with a return of -32.69%. This significantly underperformed the benchmark return of 51.69%. The strategy recorded a CAGR of -12.53% and a maximum drawdown of 0.00%, highlighting the inherent risks and volatility associated with this approach.
CEO Commentary
CEO Parth Mehrotra emphasized Privia Health’s strong performance, citing 13.8% year-over-year implemented provider growth and 15.2% value-based lives attribution growth. He noted the company’s differentiated model—combining medical groups, risk-bearing, and a tech platform—as a driver of consistent financial performance. Mehrotra expressed confidence in the business model and optimism about growth from new provider signings and operational execution.
Guidance
Privia Health raised its full-year 2025 guidance for Practice Collections, GAAP Revenue, Platform Contribution, and Adjusted EBITDA to above the high end of initial ranges. The company expects over 80% of full-year adjusted EBITDA to convert to free cash flow and anticipates ending 2025 with more than $450 million in cash, assuming no further capital deployment.
Additional News
Recent developments include the company’s $95 million acquisition of an IMS transaction in Arizona, signaling a strategic move to expand its market presence. also announced plans to host a conference call on August 7, 2025, to discuss its financial results and future outlook. No major executive changes or dividend announcements were reported within the specified timeframe.
Ainvest Earnings Report Digest
Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.
Latest Articles
Limoneira 2025 Q4 Earnings Widens Loss by 369% as Q4 Earnings Miss Expectations
Dec.23 2025
Electrovaya 2025 Q4 Earnings Record Net Income Surges 1896.5% from Loss
Dec.20 2025
Winnebago Industries 2026 Q1 Earnings Record Revenue and 205.8% Net Income Turnaround
Dec.19 2025
Paychex 2026 Q2 Earnings Beats Revenue Estimates, EPS Falls Short
Dec.19 2025
Lamb Weston Holdings 2026 Q2 Earnings 272% Net Income Surge and 1.1% Revenue Growth
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet